Tag: OTCMKTS:MDIT
MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11
ORLANDO, Fla., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTC:MDIT / OTCMKTS:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conference on Monday, January 11, 2016, at the Fairmont San Francisco.
MEDITE Cancer Diagnostics, Inc. Reports a Profitable Third Quarter and Nine Month 2015 Results
ORLANDO, Fla., Nov. 17, 2015 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT, the 'Company' / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results.
MEDITE Cancer Diagnostics, Inc. Reports 2015 Q2 and Six Month Results, Increases Equity
ORLANDO, Fla. /Florida Newswire/ -- MEDITE Cancer Diagnostics, Inc. ('Company,' OTCQB symbol: MDIT / OTCBB:MDIT / OTCMKTS:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces second quarter and six month 2015 results.
